|
- Home | NeoGenomics Laboratories
With over a decade of experience, NeoGenomics has contributed to a wealth of research, uncovering insights to advance breakthroughs in cancer diagnostics Our expertise in real-world evidence (RWE) and genomic insights helps shape the future of precision medicine diagnostics
- Login - NeoGenomics
NeoGenomics website will be undergoing maintenance on Wednesday, 1 14 26 at 9:00 PM EST (6:00 PM PST) with an estimated downtime of less than 30 minutes Please get in touch with Client Services at 866 776 5907, option 3 with any questions Important reminder!
- Search Our Test Menu | Comprehensive Testing for Providers - NeoGenomics
Quickly find the right diagnostic test with NeoGenomics’ easy-to-navigate catalog, designed to streamline the selection process for cancer care providers
- About NeoGenomics Laboratories | Healthcare Testing Solutions
NeoGenomics is committed to innovation in cancer diagnostics, providing comprehensive testing solutions to advance precision medicine for your patients
- NeoGenomics
Copyright © 2026 NeoGenomics Laboratories All rights Reserved Privacy Terms Licensing Do not sell or share my personal information
- Client support resources | NeoGenomics Laboratories
NeoGenomics is licensed under the Clinical Laboratory Improvement Amendments (CLIA) of 1988 and is authorized to provide diagnostic laboratory services in the states of California, Florida, Maryland, New York, Pennsylvania, and Rhode Island
- Login - NeoGenomics
We’re proud of the impact our teams have made and of our President and COO, Warren Stone, for sharing how NeoGenomics helps ensure patients receive high-quality care close to home through ACLA’s Power Of Knowing campaign
- NeoGenomics Reports First Quarter 2025 Results
“Our business is off to a solid start in 2025 with our team delivering a record number of results to patients in the first quarter and improving our adjusted EBITDA by over 100% from prior year,” said Tony Zook, CEO of NeoGenomics
|
|
|